Home » News » Awards & Advancement » Neurovive hires Erik Kinnman as CEO

Neurovive hires Erik Kinnman as CEO

Tuesday, February 23, 2016

NeuroVive Pharmaceutical has selected Erik Kinnman as NeuroVive’s chief executive officer (CEO). Erik Kinnman will assume the new role on the March 14, leaving chief medical officer (CMO) and chief operating officer (COO) roles within his own consultancy business.

Erik Kinnman is a seasoned life science executive with broad experience and understanding from the industry across a variety of businesses and functions. He has held a number of senior leadership positions in biopharmaceutical companies such as AstraZeneca and Sobi. His expertise and experience includes clinical development, business strategy, business development, and investor relations. Erik Kinnman also has experience from the financial sector. In addition, he holds an Executive MBA from the Stockholm School of Economics and has comprehensive scientific qualifications from the Karolinska Institutet, which has rendered him a Ph.D. and an associate professor. Moreover, Erik Kinnman is an M.D., board certified in neurology and pain management.

“The NeuroVive board and I are confident that Erik Kinnman is the right person to lead the company, its strategy, and leverage the opportunities. The combination of his strategic vision and medical expertise is an excellent fit with NeuroVive’s strategy refocused towards R&D. Erik Kinnman is a strong and experienced leader who has a proven ability to translate scientific, clinical and business strategy into execution,” said Gregory Batcheller, chairman of the NeuroVive board of directors. “He will provide expertise and focus across the organization and establish solid partnerships that will enhance our R&D program further. His broad experience grounded in research, medicine and the biopharmaceutical industry is exactly what we need to lead this organization forward.”

“I am excited about NeuroVive, the CEO role, and the opportunity to contribute to the success and growth of the company. NeuroVive is a highly innovative organization and I am convinced that it has great potential in its range of novel treatment opportunities and their commercial potential. NeuroVive and its partners are truly led by a purpose and passion to make a difference and meaningful impact to patients affected by mitochondrial disorders. I will enable our researchers and partners to deliver on the opportunities in the clinical projects, as well as in the early pipeline to drive the value of NeuroVive,” said Erik Kinnman.

Erik Kinnman succeeds interim CEO Jan Nilsson, who will resume his position as chief operating officer for NeuroVive. Jan has made significant contributions to move the organization forward. The recent partnership deals with both Isomerase and the University of Pennsylvania (UPENN) have been significant achievements under Jan’s leadership. Jan’s extensive NeuroVive knowledge and commitment to move the organization forward have been greatly appreciated by both the teams and board of NeuroVive.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!